A Study to Investigate LYL797 in Adults With Solid Tumors

IInclusion Criteria: * ≥ 18 years of age at time of informed consent * Confirmation of ROR1 expression from a pretreatment tumor sample * Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable * Platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer. * Endometrial cancer. * Measurable disease including a target lesion and an additional lesion for biopsy * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate organ and marrow function * Women of childbearing potential must have a negative pregnancy test at screening * All participants must agree to practice highly effective methods of contraception Exclusion Criteria: * Prior treatment with any adoptive T-cell therapy or other anti-ROR1 therapy * Prior solid organ transplantation * Active, untreated brain metastasis or leptomeningeal disease; however, stable, treated brain metastases are allowed * Untreated or active infection at the time of screening or leukapheresis * HIV-positive, HTLV-1-positive, active acute HAV, acute or chronic HBV or HCV, or active tuberculosis * Impaired cardiac function or clinically significant cardiac disease * Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequent), or lymphangitis carcinomatosis * History of interstitial pneumonitis or pulmonary fibrosis. * Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis * Pregnant or lactating/nursing women